Based on the Briacell Therapeutics Corp stock forecast from 0 analysts, the average analyst target price for Briacell Therapeutics Corp is not available over the next 12 months. Briacell Therapeutics Corp’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Briacell Therapeutics Corp is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Briacell Therapeutics Corp’s stock price was USD 0.40. Briacell Therapeutics Corp’s stock price has changed by -37.13% over the past week, -63.38% over the past month and -90.82% over the last year.
No recent analyst target price found for Briacell Therapeutics Corp
No recent average analyst rating found for Briacell Therapeutics Corp
Company Overview Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Read Less
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for m...Read More
Frequently Asked Questions About Briacell Therapeutics Corp (BCTX) Stock
Stock Target Advisor's fundamental analysis for Briacell Therapeutics Corp's stock is Bearish.
Unfortunately we do not have enough data on BCTX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BCTX's stock to indicate what its average analyst target is.
BCTX stock's Price/Earning ratio is 745.00.
Our analysis grades BCTX stock's Price / Earning ratio at F. This means that BCTX stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BCTX may be a overvalued for its sector.
The last closing price of BCTX's stock was USD 0.40.
The most recent market capitalization for BCTX is USD 0.03B.
Unfortunately we do not have enough analyst data on BCTX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Briacell Therapeutics Corp's stock.
As per our most recent records Briacell Therapeutics Corp has 0 Employees.
Briacell Therapeutics Corp's registered address is Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1.
You can get more information about it from Briacell Therapeutics Corp's website at https://briacell.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Briacell Therapeutics Corp (BCTX) Stock
Stock Target Advisor's fundamental analysis for Briacell Therapeutics Corp's stock is Bearish.
Unfortunately we do not have enough data on BCTX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BCTX's stock to indicate what its average analyst target is.
BCTX stock's Price/Earning ratio is 745.00.
Our analysis grades BCTX stock's Price / Earning ratio at F. This means that BCTX stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BCTX may be a overvalued for its sector.
The last closing price of BCTX's stock was USD 0.40.
The most recent market capitalization for BCTX is USD 0.03B.
Unfortunately we do not have enough analyst data on BCTX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Briacell Therapeutics Corp's stock.
As per our most recent records Briacell Therapeutics Corp has 0 Employees.
Briacell Therapeutics Corp's registered address is Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1.
You can get more information about it from Briacell Therapeutics Corp's website at https://briacell.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BCTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
